for Apr 14, 2019
Combination therapy for S. aureus #ECCMID2019 highlights “Daptomycin Plus Ceftaroline Versus Standard of Care Monotherapy in the Treatment of MRSA Bacteremia” trial stopped early b/c mortality in combination 0% vs vancomycin 26% https://t.co/i1Cz8mJnmR
— 𝙀𝙡𝙞 𝙋𝙚𝙧𝙚𝙣𝙘𝙚𝙫𝙞𝙘𝙝 😷 (@eliowa) April 14, 2019
Procalcitonin-guided antibiotic therapy associated with reduced antibiotic exposure, side effects and mortality. Important to have #AntimicrobialStewardship guidance to ensure results acted upon. #ECCMID2019 via Dr. Thomas Filehttps://t.co/XGxOAaRGNX
— Brad Langford (@BRxAD) April 14, 2019
If you are interested in 🆔@IDstewardship and @ABsteward
— Antibiotic Steward (@ABsteward) April 14, 2019
identify new infectious diseases & antimicrobial stewardship literature released each month . Hot off the press and put together in one place. #ECCMID2019 #IDTwitter @TAEscmidhttps://t.co/Z1qtRHkcQp
Register [FREE] for RApid Diagnostics for Antimicrobial Resistance (RADAR) event @UniStrathclyde on Mon 29th April (12-5pm) organised by @DamionCorrigan & @JimenezMelanie_ please RT https://t.co/kL4QIsFgiC #AMR #antibiotics #diagnostics #AntimicrobialStewardship pic.twitter.com/dbODybFkwV
— Paul Hoskisson 🔬🧫🧬🐸🐍🦎🐢 (@PaulHoskisson) April 14, 2019
Worldwide, the irrational use of antibiotics and poor antimicrobial stewardship lead to treatment failure and propagate the spread of drug resistance, says the studyhttps://t.co/029GDluHBb
— Livemint (@livemint) April 14, 2019
***NEW! Impact of antimicrobial therapy on the gut microbiome. AMS programs should consider these findings in their empiric guidelines. #JAC #ECCMID2019 #microbiome #AMS https://t.co/rRVDnxbea4
— NCAS_Australia (@NCAS_Aus) April 14, 2019
Antibiotic trials discussed by Christina Mussini in year in ID session: (1) colistin alone vs colistin+meropenem for severe infections caused by carbapenem-resistant Gram-negative bacteria https://t.co/7VtYlSpWX4 #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
Looking forward to reading this new open access journal announced at #ECCMID2019 JAC-Antimicrobial Resistance focuses on research, practice, and education on @BSACandJAC #AntimicrobialStewardship https://t.co/xQflqzeaZN
— Brad Langford (@BRxAD) April 14, 2019
#ECCMID2019 tweets & interactions to end of day 2 via NodeXL https://t.co/4Upny2HnCq@escmid@taescmid@absteward@naturerevmicro@thelancetinfdis@davidvanduin@nanopore@jdelpoleo@eccmid@emrsa15#AntimicrobialStewardship #InfectiousDiseases
— Dr Graham Mackenzie🇪🇺 (@gmacscotland) April 14, 2019
Some hashtag drift (#ECCMID19)
'Superbugs' found on many hospital patients' hands & what they touch most often.
— Microbes&Infection (@MicrobesInfect) April 14, 2019
14% of hospital patients had antibiotic-resistant bacteria on hands or nostrils early in their hospital stay, & bacteria found on objects that patients touch in their rooms.https://t.co/NHFSisACP3 pic.twitter.com/261Whmrk94
Dr. Thomas File: recent meta-analysis shows reduced mortality associated with antibiotic duration of 6 days or less for community acquired pneumonia #ECCMID2019 https://t.co/FSxOpvIRlv
— Brad Langford (@BRxAD) April 14, 2019
Editorial: JAC-Antimicrobial Resistance ( JAC-AMR ) a novel open access journal for research and education https://t.co/xQ2RxYWTnL
— Antibiotic Action (@TheUrgentNeed) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
2- OVIVA Trial: Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first 6 weeks for complex orthopedic infection, as assessed by treatment failure at 1 year. https://t.co/WK4SZGqDLQ
Emilia Cercenado highlights this study on diagnostic accuracy of Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance #ECCMID2019 https://t.co/fBflbVHsxJ
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
Could Treating Gut Bacteria Help Autism Symptoms?
— Microbes&Infection (@MicrobesInfect) April 14, 2019
The small study of 18 children with #autism who also had severe digestive problems found that a fecal transplant to rebalance their gut #microbiome reduced both digestive symptoms & autism symptoms.https://t.co/dvoMkWumCy #FMT pic.twitter.com/csxZvrJEpG
Why is it difficult to change prescribing behaviour with #RapidDiagnostics? Ruling in a viral infection does not rule out a bacterial #infection. Need to adres clinicians fear for undertreatment. #ECCMID2019 #AntimicrobialStewardship pic.twitter.com/keUkyGGEhk
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
13- Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial https://t.co/YcZ9bgFtN9 @IDSAInfo @mugecevik
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
12- Ceftazidime-avibactam was non-inferior to meropenem in the treatment of nosocomial pneumonia. https://t.co/wXcvCg5eU1 @TheLancetInfDis @onisillos @mugecevik
I.Barber Senior VP Clinical Marketing #ECCMID2019 . The Power of Data in #AntimicrobialStewardship :There is an increasing role of IT Solutions in AMS to deliver results to the right person to rapidly take a patient management decision https://t.co/0R97egmbXC #DiagnosticsIsPower pic.twitter.com/y5Fg8Zs8qZ
— bioMérieux (@biomerieux) April 14, 2019
We need an antimicrobial stewardship teams to have oversight to make recommendations on the duration of antibiotic therapy in pneumonia based on new diagnostics Thomas File #ECCMID2019 good reference to our review https://t.co/s8eDCfX13r
— Till Bachmann (@BachmannTill) April 14, 2019
Laurent Verdier - Global Marketing Director bioMérieux explains at #ECCMID2019 "We are working to improve, to make better and ultimately impact patient care" https://t.co/vYa8GKDkSK #AntimicrobialStewardship pic.twitter.com/9BRCW0Cduz
— bioMérieux (@biomerieux) April 14, 2019
A new study suggests that hospitals need to disseminate the idea of washing hands, to their patients too, apart from their staff. The study was published in the Journal 'Clinical Infectious Diseases'.https://t.co/M9GbRnZrex
— TIMES NOW (@TimesNow) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
8- IV cefiderocol three times daily was non-inferior compared with imipenem-cilastatin for the treatment of complicated urinary tract infection in people with multidrug-resistant GNB https://t.co/kSrjmAUEbd @TheLancetInfDis
PK-PD is not just about kill and initial clinical cure. Optimal antibiotic exposures are associated with prolonged and sustained killing as well as suppression of resistance— the latter of which is underappreciated yet so important #ECCMID2019 https://t.co/Rl3ALdoNgb pic.twitter.com/65qOCyAy1b
— Erin McCreary (@ErinMcCreary) April 14, 2019
C. difficile associated with longer duration of antibiotic therapy for community acquired pneumonia in this prospective cohort study #ECCMID2019 via Dr. Thomas File https://t.co/y3UYkJFoJU
— Brad Langford (@BRxAD) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
5- Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial https://t.co/uLgX0BfDfI @TheLancetInfDis @onisillos
Who listens and who doesn't? Factors associated with acceptance of #AntimicrobialStewardship recommendations in a Singapore hospital. Carbapenem use, de-escalation, surgical admission and written rec associated with ⬇️ likelihood of acceptance #ECCMID2019 https://t.co/NHajzVDCHx pic.twitter.com/0AePFLz1Nm
— Brad Langford (@BRxAD) April 14, 2019
“Antimicrobial resistance is one of the most concerning public health threats that we face,” says Dr. Anthony Fauci, head of @NIAIDNews https://t.co/Qd5SuD5nq2
— Save Antibiotics (@saveantibiotics) April 14, 2019
L.Verdier Global Marketing Director "We're here to learn a lot from our customers. It's all about the interactions & providing solutions based on needs expressed by customers & a wider audience. We are here to serve #AntimicrobialStewardship " https://t.co/DZMbl4RQ25 #ECCMID2019 pic.twitter.com/DYOHqKjjwy
— bioMérieux (@biomerieux) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
10- Once-daily plazomicin was noninferior to meropenem for the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriaceae, including multidrug-resistant strains https://t.co/rRrxh115iV @NEJM @mugecevik
Here's the link to the systematic review and meta-analysis associating #AntimicrobialStewardship initiatives in long-term care with a 14% reduction in antibiotic use https://t.co/yIFehwzwEd#ECCMID2019 @AntibioticLeeds pic.twitter.com/Lc2E7S6MtW
— Brad Langford (@BRxAD) April 14, 2019
I wanted to mock ads in my talks that promote antibiotic overuse. Some folks say I can't, citing "Standard 4.3" from @AccreditedCME. Really? Latest post, with h/t to @VPrasadMDMPH for articulating what most educators aren't bold enough to say. https://t.co/o2X1cLaXUS
— Paul Sax (@PaulSaxMD) April 14, 2019
#HIV studies highlighted by Cristina Mussini: (1) Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2) https://t.co/rCwV1McHYM #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
New @TheLancetHIV: Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries https://t.co/HoQTafoGd1
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
#measlesoutbreak kills > 1,200 in Madagascar.
— Microbes&Infection (@MicrobesInfect) April 14, 2019
Unlike the case in the US and parts of Europe, parents in Madagascar would like to vaccinate their children but face immense challenges, including lack of resources.https://t.co/FqMUOtB85T #measles
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
4- Procalcitonin use to shorten treatment: PCT use did not decrease the use of antibiotics https://t.co/lz9IHVukx5 @NEJM
Year in Infectious Diseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
Studies mentioned with links to the papers:
1- Zika virus persistence in body fluids published @NEJM https://t.co/cvOQUI6wQF
Giovanni Rezza is discussing tropical outbreaks in temperate areas. He was first author of 2007 @TheLancet paper on #chikungunya in Italy 🇮🇹, which sparked his interest https://t.co/Ci5LXKBerd #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
And: (2) ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia https://t.co/WWnu8sWYfz #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
Insect-borne diseases such as #dengue #leishmaniasis & #encephalitis are on the rise & are now threatening to spread into many areas of Europe.
— Microbes&Infection (@MicrobesInfect) April 14, 2019
Outbreaks of the illnesses increasing because of #climate change & expansion of international #travel & #tradehttps://t.co/0i3Pzllimz pic.twitter.com/blaGALM5s0
#ECCMID2019 Cristina Mussini: year in ID.#AntimicrobialStewardship
— Dr. Alicia (@aliciad3) April 14, 2019
-MERINO trial @JAMA_current. Still recommends meropenem (not pip/tazo) for E coli and Klebsiella resistant to ceftriaxone.
but DO NOT USE MEROPENEM WHEN NOT NECESSARYhttps://t.co/pEYj4pEyKx
Nice NIH NIAID blog on our Cell paper! Parasites on the Clock: How Malaria Races against Mosquito Reproduction | NIH: National Institute of Allergy and Infectious Diseases https://t.co/U5Ssm27rMf via @AddThis
— Flaminia Catteruccia (@flamcatt) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
6- MORDOR study: Mass distribution of Azithromycin decreased childhood mortality. ?#antimicrobialresistance https://t.co/jlsmqzYKMN @NEJM @mugecevik
Successful use of DOOR (Desired Ordinal Outcome Ranking) to evaluate the impact of an #AntimicrobialStewardship initiative on a family medicine ward #ECCMID2019 @IDPharmProfhttps://t.co/OIOEvCY7uv
— Brad Langford (@BRxAD) April 14, 2019
Link to empirical antibiotic selection tool from session S0062 yesterday #ECCMID2019 (which seems to work well) https://t.co/ia41MTThBF pic.twitter.com/6p593Vj8ah
— Jonathan Sandoe (@j_sandoe) April 14, 2019
#ECCMID2019 day 2 via @TwitonomyApp @TAEscmid @SouthAfricanASP @ErinMcCreary @TheLancetInfDis @doctorsanjay @mugecevik @CrisSuFe @AAD_Japan @dfeatamr
— Dr Graham Mackenzie🇪🇺 (@gmacscotland) April 14, 2019
Report https://t.co/llLMtXPQZH
Map https://t.co/2cqdjHvw2y#InfectiousDiseases #AntimicrobialStewardship #ClinicalMicrobiology pic.twitter.com/x9Ew7Xrvgb
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
11- MERINO Trial: https://t.co/lJVStOb8tS
#مؤتمر_سلامة_المرضى_التاسع Sign up now for a full schedule of wholesome continuing education in #patientsafety including a workshop on: #ASP: practical tips on how to set up an #antimicrobialstewardship program. Registration: https://t.co/DYh5W227rB https://t.co/h8XFUQDfy7
— Nour Shamas (@Nour_shamas_ID) April 14, 2019
Wecome to #ECCMID2019 Amsterdam. I. Barber Senior VP Clinical Marketing "We are looking forward to showcasing how diagnostics plays a key part in #AntimicrobialStewardship Programs & partner with microbiology labs to raise the importance of Dx in #AMS https://t.co/nyIUhQZX8q pic.twitter.com/QWFyZcmexW
— bioMérieux (@biomerieux) April 14, 2019
Jewish neighborhood in New York, US, grapples with #measles outbreak.
— Microbes&Infection (@MicrobesInfect) April 14, 2019
Most of the community is vaccinated - rabbis stress there is no religious reason against it. But claims that vaccines are not kosher or cause autism have been spread by #antivaxxershttps://t.co/cqmoGhRPvG pic.twitter.com/4Ueu4Ty4UD
Mayor of New York, US, declared a public health emergency, warning that all unvaccinated people in Brooklyn will be required to receive the #MMR vaccine.
— Microbes&Infection (@MicrobesInfect) April 14, 2019
The emergency was declared due to a #measlesoutbreak among ultra-Orthodox Jews who live in the area.https://t.co/juiaQkdIEX pic.twitter.com/lzTcCdfyMW
Petting #zoo is a breeding ground for #drug-resistant #superbugs & #antibiotic residues in #wastewater also spread this pressure into #streams & other environments. https://t.co/QQwms1Tc5q @nisusveterinary #AMR #AntibioticResistance #AntimicrobialStewardship #bacteria #pathogens
— Nisus Animal Health (@nisusveterinary) April 14, 2019
Pierre Tattevin discusses PhagoBurn trial of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa #ECCMID2019 https://t.co/R0E1pLIUhw
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
‘Ecological study identifies potential association between antimicrobial resistance & climate change’ #StopSuperbugs https://t.co/sgIyVHx6XB via @EurekAlert
— Antibiotic Action (@TheUrgentNeed) April 14, 2019
On BacterioFiles: Pigmented bacteria can be used in a cancer imaging technique that combines light and sound! https://t.co/j2T0zkxjTM
— ASM (@ASMicrobiology) April 14, 2019
But many recognized leaders in Inf Dis and HIV in Spain and a commitment to AMS as seen in this position paper: https://t.co/GR7yhR2oSv
— Carlos del Rio (@CarlosdelRio7) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
17- GEMINI 1 & 2: Dolutegravir plus lamivudine was non-inferior compared to the guideline-recommended three-drug regimen at 48 weeks in ART-naive adults https://t.co/psDV9WSXbx @mugecevik @BritishHIVAssoc
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
7- Antibiotic prescription for febrile children in European emergency departments: a cross-sectional, observational study: Highly variable abx prescription, with frequent second line treatment Rx https://t.co/Iumy2dLFyQ @TheLancetInfDis
Some challenges in Spanish hospitals where #InfectiousDiseases is not recognised speciality. Little input of #AntimicrobialStewardship in #oncology #ECCMID2019 @ESGAP_ABS @UKCPAPIN @FIP_org @EAHPtweet pic.twitter.com/iMzIYZfFXJ
— Philip Howard (@AntibioticLeeds) April 14, 2019
In her section on #tuberculosis Cristina Mussini discusses this meta-analysis: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis https://t.co/1wrguyJqVe #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
#ECCMID2019 This @BostonChildrens study showed that while vancomycin trough was lower than target using recommended dose in children, AUC/MIC was appropriate.
— Dr. Alicia (@aliciad3) April 14, 2019
Perhaps we need to rethink target trough or outcome measurement?
cc @tomsandorahttps://t.co/YKrEvawLBw
More for your Monday #ECCMID2019 itinerary! Posters by @SIDPharm members & colleagues @Crasspofungin @DosingMatters @pillsandskills @EmilySpivak @TimbrookTT, M. Mehta, M. Sweet, L. Keller, @penicillinman https://t.co/mqc5jAM1irhttps://t.co/5mC2tX5N6Ohttps://t.co/Rixre0Dzyx pic.twitter.com/sYM2pqizHE
— SIDP (@SIDPharm) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
9- Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea: The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin https://t.co/aYyRfFFynv
#ECCMID2019 Celia Souque @Celia_Sqe on Bugs in Bangkok: Creating a boardgame to fight antimicrobial resistance in Thailand
— Dr. Alicia (@aliciad3) April 14, 2019
cc @eBug_UK #boardgameshttps://t.co/fleECjy8b2
European experts sound alarm as mosquito- and tick-borne diseases set to flourish in warmer climate https://t.co/hJZIhtzfU7 European Congress of Clinical Microbiology & Infectious Diseases shows that the geographical range of vector-borne diseases is expanding rapidly. @CDCGov
— Bay Area Lyme Fndn (@BayAreaLyme) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
15- 4-month rifampin was not inferior to the 9-month regimen of isoniazid for the prevention of active tuberculosis and was associated with a higher rate of treatment completion and better safety. https://t.co/q1klm2gJqS @NEJM
‘Petting zoos a breeding ground for drug-resistant superbugs, study finds’ #StopSuperbugs https://t.co/7Eq4AjQvnf
— Antibiotic Action (@TheUrgentNeed) April 14, 2019
What is the impact of #ClimateChange on infectious #diseases? ECDC expert Jan Semenza will discuss this in his presentation at #ECCMID2019 today.
— ECDC (@ECDC_EU) April 14, 2019
Are you at the conference? Head to Hall B at 14:45! https://t.co/SLXUO25Ffl
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
16- In persons with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides, a short regimen was noninferior to a long regimen https://t.co/tYibA9puJ1 @NEJM
5 Essential and 4 Additional #AntimicrobialStewardship activities for hospitals in Australia. Resources and tools for stewardship were identified as potential enablers for better implementation. #ECCMID2019 @NCAS_Aus pic.twitter.com/MsbW9L749v
— Brad Langford (@BRxAD) April 14, 2019
According to a quantitative analysis of publicly available WHO vaccine data, #vaccines cause 2875x more harm, #death, and serious adverse reactions than all childhood infectious diseases combined.
— Coerced Tax Slave (@CoercedTaxSlave) April 14, 2019
Vaccines also #kill. It's one of the many side effects.https://t.co/nM9JFyNCWV
Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. #IDTwitter #ECCMID2019 https://t.co/22yCCZO66w
— Antibiotic Steward (@ABsteward) April 14, 2019
Top Tweet analysis of #Quality2019
— Fran Kerr (@Frankerr1F) April 14, 2019
Top tweeters , top tweets per day and summary of the top tweets out of nearly 7000 tweets!
Bring back good memories of @QualityForum or use for CPD!
Thanks to @gmacscotland for all his help 😀https://t.co/Clynd4DaO9
(2) Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1 https://t.co/z7HmmYAVla #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
Year in #InfectiousDiseases #ECCMID2019
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
14- M72/AS01E provided 54.0% protection for M. tuberculosis–infected adults against active pulmonary tuberculosis disease, without evident safety concerns. https://t.co/NLlBAOYVJV @NEJM
Europe is on the cusp of a major health threat from insect-borne tropical diseases such as #dengue & #chikungunya as #climate change shifts weather patterns across the continent & people move around morehttps://t.co/rhZ6V4Fj7t pic.twitter.com/z2sXB2XzCu
— Microbes&Infection (@MicrobesInfect) April 14, 2019
Systematic review and inventory of tools for #AntimicrobialStewardship in long-term care. Nods to Canadian work from @AMMICanada and @PublicHealthON#ECCMID2019https://t.co/L3DBPZc8O8 pic.twitter.com/cRcXkZLn5I
— Brad Langford (@BRxAD) April 14, 2019
Definitions and guidelines for research on antibiotic persistence. https://t.co/KyoqT7Wb6H
— AntibioticResistance (@AntibioticResis) April 14, 2019
📸 Here is a nice slide from #ECCMID2019 happening this week. This slide via TAEschmid on Twitter. Remember these when considering antibiotics for 🏥 critical care patients. #Antibiotics… https://t.co/Idbs9E1Zl2
— Bug Pharmacist (@IDstewardship) April 14, 2019
Global Point Prevalance Survey Meeting pre #ECCMID2019: key participants exchanged on country data learnings on Antimicrobial Consumption & Resistance. Free to join & enroll:+800 countries +80 hospitals +250 000 patients. bioMérieux sole private sponsor #AntimicrobialStewardship pic.twitter.com/9FoymtJc0R
— bioMérieux (@biomerieux) April 14, 2019
Which path will you choose? As a microbiologist, you have endless career paths and navigating them is your journey. Consider the career path Sandra Dworatzek took to become a Senior Manager at @SiREM, an environmental laboratory: https://t.co/LnRVwyFUub pic.twitter.com/3jl7Lk2gSC
— ASM (@ASMicrobiology) April 14, 2019
#ECCMID2019,@e_charani Wonderful talk on the social aspects and strong resolve to develop antimicrobial stewardship program with examples from a lot of studies. Loved it. pic.twitter.com/1F84VgYZQh
— Anusha Rohit (@AnushaRohit) April 14, 2019
Effects of Sequential Influenza A(H1N1)pdm09 Vaccination on Antibody Waning | The Journal of Infectious Diseases | Oxford Academic https://t.co/RbyHkl5EQG
— D. Marie (@itsmepanda1) April 14, 2019
Important to consider the #barriers for the #implementation of #AntimicrobialStewardship in surgical and medical teams. #ECCMID2019 #InfectiousDiseases pic.twitter.com/0voe5J4xPY
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
#ECCMID2019. Jan Semenza @ECDC_Outbreaks explains how to foresee threatening scenarios of infectious diseases is complex because it is the result of multiple factors. Could we imagine the next influenza pandemic if we were aware of all these factors?https://t.co/HDFBAb8J3j pic.twitter.com/WNW3yPHnn8
— Centro Nacional de Gripe de Valladolid (@CentroGripe) April 14, 2019
An #interdisciplinary approach with the involvement of #Pharmacists and #Nurses is important for the succesful #implementation of #AntimicrobialStewardship. Great talk by @e_charani at #ECCMID2019 pic.twitter.com/q2cG30gsPE
— Trainee Association of ESCMID (@TAEscmid) April 14, 2019
Great study highlighted in #ECCMID2019 by @SIDPharm @Kerry_LaPlante @IDroadrunner
— Antibiotic Steward (@ABsteward) April 14, 2019
Clinical Data on Daptomycin Plus Ceftaroline VS. Standard of Care Monotherapy in the Treatment of MRSA Bacteremia. 👏 #IDTwitter https://t.co/xEuVFDezXw
This is the paper on Antibiotic prescription for febrile children in European emergency departments https://t.co/LzkeQxlcHC #ECCMID2019 https://t.co/ElnSMgQOCy
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
Useful algorithm for stopping antibacterials in flu +ve patients on treatment if PCT <0.1 #ECCMID2019 @UKCPAPIN @BSACandJAC @LTHTAntibiotics @FIP_org @ESGAP_ABS pic.twitter.com/P6vaFuFko6
— Philip Howard (@AntibioticLeeds) April 14, 2019
Desired Ordinal Outcome Ranking (DOOR) to evaluate effect of antimicrobial stewardship interventions on a family medicine ward. Great work @n_mercuro @IDPharmProf @SIDPharm #ECCMID2019 #IDTwitter https://t.co/43hg2eSkeu
— Antibiotic Steward (@ABsteward) April 14, 2019
(3) Viral suppression and HIV transmission in serodiscordant male couples https://t.co/FIhZj619DI #ECCMID2019
— The Lancet Infectious Diseases (@TheLancetInfDis) April 14, 2019
Favourite presentation so far at #ECCMID2019 @ESCMID @EveTacconelli giving an outstanding overview about the intersection of the current status of microbiome knowledge and research and antimicrobial stewardship. @NCICancer pic.twitter.com/5Slg4UtG5X
— NCAS_Australia (@NCAS_Aus) April 14, 2019
Top Influencers of #ECCMID2019 👉 @aliciad3 @MicrobLog_me_uk @TAEscmid @ABsteward @ESCMID @biomerieux https://t.co/OReWbZZCTA via @symplur
— Antibiotic Steward (@ABsteward) April 14, 2019
Jorgen Jensen with his experiences of our beta-test for Mgen ParC mutations conferring resistance to second-line therapy at the SpeeDx Satellite Symposium #ECCMID2019 #ResistanceGuidedTherapy #AntimicrobialStewardship #AntimicrobialResistance pic.twitter.com/fmnV72mXf0
— SpeeDx (@speedx) April 14, 2019
#ECCMID2019 #AntimicrobialStewardship Van Belkum indicates PCT is faster and more specific than CRP to determine bacterial or viral infection pic.twitter.com/mPxUCoPA3E
— bioMérieux (@biomerieux) April 14, 2019
Desired ordinal outcome ranking (DOOR) method for measuring#AntimicrobialStewardship in #USA hospital #ECCMID2019 @UKCPAPIN @ESGAP_ABS @FIP_org @BSACandJAC @BSACPresident pic.twitter.com/tVPNvwx2EE
— Philip Howard (@AntibioticLeeds) April 14, 2019
Fantastic.
— ErinKate Stair (@DrErinkate) April 14, 2019
Also why you should want to end illegal wildlife trade? It's a big cause for emerging infectious diseases. Usually diseases much worse than measles too. https://t.co/lARj4vHa29
Thank you @nytimes for raising awareness on the importance of #antimicrobial #stewardship and the spread of drug resistant #Candidaauris. The Karius Test can non-invasively detect this #fungus to assist in the diagnosis of #fungal #infections. https://t.co/dSGDQaUEIE
— Karius, Inc. (@kariusdx) April 14, 2019
What is antibiotic prescribing other than making decisions under uncertainty?
— ESGAP_ABStewardship (@ESGAP_ABS) April 14, 2019
Come by #HallE to this foundational topic for #AntimicrobialStewards https://t.co/2wYARDWfao@AntibioticLeeds
Analysis scripts and supplementary files: Barriers to implementing clinical trials on non-pharmacological treatments in developing countries – lessons learnt from addressing pain in #HIV:https://t.co/dQrt5SxoAL #infectiousdiseases
— figshare (@figshare) April 14, 2019
Vaccine hesitancy is threatening the historical achievements made in reducing the burden of infectious diseases, which have plagued humanity for centuries (Op-Ed) https://t.co/NSizMam2Go via @LancetChildAdol pic.twitter.com/kAIxhmgfdH
— Marc Gozlan (@MarcGozlan) April 14, 2019
WATCH: antibiotic innovation expert discusses the challenges & potential solutions for drug discovery https://t.co/sKADrhzSLF
— Save Antibiotics (@saveantibiotics) April 14, 2019
#ECCMID2019 Salam Abbara @salam_isme on "Infectiologique": a serious game to learn antibiotics prescribing.
— Dr. Alicia (@aliciad3) April 14, 2019
Will launch in France in September 2019.
Renamed "Dawaa", for "treatment" or "medication" in Arabic.
cc @eBug_UK @e_bug_francehttps://t.co/V5OrxjumzJ
National handwashing campaign reduces incidence of Staphylococcus aureus infection in Australia's hospitals: European Society of Clinical Microbiology and Infectious Diseases Since its implementation in 2009 the National Australian Hand Hygiene… https://t.co/k7n4RiP6nh
— Clinical Trials News (@ClinicalPhase) April 14, 2019
Staying in a hotel during travel to tropical regions is associated with contracting drugresistant bacteria with younger travelers aged 2030 years at highest risk: European Society of Clinical Microbiology and Infectious Diseases Staying in a hotel or… https://t.co/6CRHU699Lg
— Clinical Trials News (@ClinicalPhase) April 14, 2019
Created by Cameron Forbes. Last updated April 19, 2019 at 07:34 EST.